Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075764 · ClinicalTrials.gov registry record · Phase 3
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 695
- Enrollment target
NCT00075764 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 695 participants.
The verdict
NCT00075764, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 695 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.
Interventions
- DRUG fulvestrant
- DRUG anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2004-04 |
| Est. Completion | 2018-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075764
The ClinicalTrials.gov registry entry for NCT00075764 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 695 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fulvestrant is the first listed.
NCT00075764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075764 about?
NCT00075764 is a clinical study titled "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cance...
What is the current status of trial NCT00075764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 695 participants. The study started on 2004-04. Estimated completion is 2018-10-01.
What interventions are being tested in trial NCT00075764?
The interventions under investigation include: fulvestrant (DRUG), anastrozole (DRUG).
Who is sponsoring clinical trial NCT00075764?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.